The neutrophil-to-lymphocyte ratio (NLR) is an inflammatory marker which has been
investigated as a prognostic indicator in post-therapeutic recurrence and survival of patients …

Advanced hepatocellular carcinoma (HCC) carries a dismal prognosis and the current
treatment is limited to sorafenib, an agent with modest benefit. Preclinical data have …

Background The prognosis for patients with hepatocellular cancer (HCC) undergoing
transarterial therapy (TACE/TAE) is variable. Methods We carried out Cox regression …

Backgrounds Neutrophil-lymphocyte ratio (NLR) has recently been reported as a predictor of
Hepatocellular carcinoma (HCC). However, its prognostic value in HCC still remains …

Background: At least 30% of patients with primary resectable non-small cell lung cancer
(NSCLC) will experience a relapse in their disease within 5 years following definitive …

There is increasing evidence that systemic inflammation markers like neutrophil (NLR) and
platelet‐to‐lymphocyte ratios (PLR) may play a role in the outcome of hepatocellular cancer …

The neutrophil-to-lymphocyte ratio (NLR) is a useful biomarker that reflects systemic
inflammation responses. However, the prognostic value of the NLR in patients with primary …

Background and aims Numerous reports have indicated that preoperative Neutrophil-
Lymphocyte ratio (NLR) was correlated with the prognosis of hepatocellular carcinoma who …

The pathogenesis of hepatocellular carcinoma (HCC) strongly relates to inflammation, with
chronic up‐regulation of pro‐inflammatory mediators standing as a potential unifying …

Results Overall, 598 papers were identified, of which 90 papers including 20,475 HCC
patients were finally included. Low baseline NLR was significantly associated with better …